KR20150135602A - Composition containing extrusion moulded astrodia elata Blume for enhancing blood circulation - Google Patents

Abstract

The present invention relates to a composition comprising an extrusion-molded Gastrodia elata Blume extract as an active ingredient for improving blood circulation. According to the present invention, an extrusion-molded Gastrodia elata Blume extract can be used as a health functional food or medicine useful for preventing or treating thrombosis, which represents excellent effects in improving blood circulation and antiplatelet effects, by inhibiting platelet aggregation and generation of thromboxane B2, and extending the bleeding time.

Description

TECHNICAL FIELD The present invention relates to a composition for improving blood circulation comprising an extrusion-

The present invention relates to a composition for improving circulation comprising an extruded chymase ( Gastrodia elata Blume) as an active ingredient.

Recently, circulatory diseases such as arteriosclerosis, cerebral hemorrhage, hypertension, heart disease, stroke, and cerebral infarction have been the leading causes of death in Korea as well as in developed countries. These geriatric diseases have developed into modern society, and are frequently occurring in middle and old age due to changes in dietary patterns and internal and external environmental stresses. A variety of causes can block the blood vessels and cause the diseases. If the cardiovascular system is blocked, myocardial infarction can occur. If the blood vessels in the brain are blocked, a cerebral infarction can occur. In the case of cerebral infarction, the disease may continue to progress, resulting in a stroke and death. In the United States, stroke is the third most common cause of death in adults and is known to be the most important cause of mobility. The main cause of these diseases is known as thrombus. Thrombosis is recognized as a pathological phenomenon mediated by excessive platelet aggregation. In addition, this causes a disorder of blood circulation.

Hemostasis is a mechanism to prevent hemorrhage from broken blood vessels. The hemostasis is accomplished through the activation process of platelets, the adhesion of platelets and blood vessels, and the complex interactions of blood coagulation factors that accompany them, restoring damaged blood vessels. Platelets are activated by stimulation of various agonists such as collagen, arachidonic acid, and adenosine diphosphate (ADP) during vascular injury to induce adhesion, secretion, And aggregation. These reactions are associated with haemostasis and are also known to be involved in the onset of circulatory diseases, including thrombosis.

Platelets have a distinctive discoid shape in the resting state, but when activated, they lose their original shape and undergo irregular shaped deformations with females, and the polymerization of cytoskeleton species, , Phosphorylation and the resulting interactions.

The antiplatelet agents developed so far include theopylline, molsidomin, verapamil, and nifedipine. It is known for promoting the formation of cAMP and cGMP inhibit the mobilization of Ca ^{+ 2.} Nonsteroidal compounds such as aspirin, imidazole, and indymethacin are also known to have antiplatelet activity by inhibiting the production of thromboxane A2. However, the drugs made of the above-mentioned chemicals have various problems such as excessive hemostasis, infertility and digestive disorders in the human body. Accordingly, in order to search for a substance showing the same effect while reducing side effects of drugs made of the above-mentioned chemical substances, many researches on substances that improve blood circulation from natural substances have been conducted.

Meanwhile, Pegasus (天麻, Gastrodia Rhizoma) is not a leaf chlorophyll as referring to the root of the number of perennial plant belonging to the orchid neck Orchidaceae (Orchidaceae) native to Japan, Korea, China and other self-harm fucked (Pegasus, Gastrodia elata Blume) Is a medicinal crop with the characteristics that it grows by receiving nutrition from the parasitic fungus. The stem is like a potato and the grain is arranged on the surface. The stem is a column of yellowish red color and the height is about 1m. It is a yellow-flowering plant in menstruation. It is also called the other names such as red roots, 鬼 之 宇, 麻 母, 神 草, and 风风 草. The major constituents of chima are gastrodine, p- hydroxybenzaldehyde (HBAD), p- hydroxybenzyl alcohol (HBA), vanillyl alcohol (VA), vanillin, parishins B, C, 4,4-dihydroxybenzyl sulfoxide and gastrol. Ginseng is a medicinal herb that is classified as medicinal herb and has a weakness as a medicinal herb. Clinical efficacy of Chunma is found in various herbal medicines such as herbaceous gangbuk and Dongbibogam. It is known to be effective for diseases such as hypertension, headache, paralysis, neurological diseases, diabetes, and stress and fatigue.

The extrusion molding process is a single process in which unit operations such as mixing, cutting, crushing, puffing, and sterilization take place in a short time. It is an efficient and economical process as compared with other heat treatment process and can be used for hydration, swelling, And dextrinization, denaturation of proteins, inactivation of enzymes, microbial killing and sterilization, removal of odor, tissue expansion, density control and browning reaction, and increased extraction yield of active ingredients have been reported. In addition, since the properties of the desired product can be controlled according to the feed rate, the moisture content, the screw rotation speed, the structure of the discharge port, and the arrangement of the screw, the product having various characteristics can be produced.

As described above, various pharmacological effects of chima are known, but it has not yet been clarified whether extruded chima is effective for improving blood circulation. Therefore, the inventors of the present invention completed the present invention by confirming that the extract of extruded horse chestnut has an excellent blood circulation improving effect when a new drug having blood circulation improving effect was developed by using extruded chimpanzees.

An object of the present invention is to provide a composition for improving circulation comprising an extruded ginger root extract as an active ingredient.

It is another object of the present invention to provide a composition for preventing or treating a thrombotic disease comprising an extruded chimmeal extract as an active ingredient.

 In order to achieve the above object, the present invention provides a composition for improving circulation comprising an extruded chimme extract as an active ingredient.

In addition, the present invention provides a composition for preventing or treating thrombotic diseases comprising an extruded chimme extract as an active ingredient.

The extruded chimmeal extract according to the present invention inhibits the platelet aggregation inhibition and the production of thromboxane B ₂ and prolongs the bleeding time to exhibit an excellent blood circulation improving effect and an anti-platelet effect. Therefore, the medicament useful for preventing or treating thrombotic diseases, It can be used as a health functional food.

FIG. 1 is a graph showing the results of measuring platelet aggregation inhibitory effect after extruded chymarpain extract was administered to the blood of rats.
2 is a diagram showing the results of the measurement of the thromboxane B ₂ production-inhibiting effect of the extract extrusion thousand miles.
FIG. 3 is a graph showing the results of measurement of inhibitory effect on platelet aggregation in a rat fed with extruded Chimmae extract.

The present invention provides a composition for improving circulation comprising an extract of Gastrodia elata Blume as an active ingredient.

The composition comprises a pharmaceutical composition or a food composition.

Hereinafter, the present invention will be described in more detail.

In the composition of the present invention, the extruded Chimma extract, which is an active ingredient, is extruded at a temperature of 120 to 180 DEG C and a pressure of 20 to 100 bar, and then extruded into a mixture of water and an alcohol having 1 to 4 carbon atoms, And then extracting the solution using at least one solvent selected from a mixed solvent. The alcohol having 1 to 4 carbon atoms is methanol or ethanol, preferably ethanol. The extraction temperature may be 50 to 100 占 폚, preferably, a hot water extraction or a reflux cooling extraction method. In one embodiment of the present invention, it was confirmed that the extruded Chimmae extract had an anti-platelet effect by inhibiting the platelet aggregation and the production of thromboxane B ₂ .

The present invention provides a composition for preventing or treating thrombotic diseases comprising an extruded chimme extract as an active ingredient, because the thrombotic disease can be prevented or treated through the anti-platelet effect.

The composition comprises a pharmaceutical composition or a food composition.

The thrombotic disease includes, but is not limited to, arterial thrombosis, venous thrombosis, pulmonary embolism, chronic venous ischemia, varicose veins, deep vein thrombosis, arteriosclerosis, cerebral hemorrhage, stroke or cerebral infarction.

The extruded chewing gum extract according to the present invention inhibits the platelet aggregation inhibition and the production of thromboxane B ₂ and prolongs the bleeding time to exhibit an excellent blood circulation improving effect and an anti-platelet effect, and thus is useful for preventing or treating thrombotic diseases .

The composition of the present invention may contain one or more known active ingredients having blood circulation improving effect together with the extrusion-molded gelatin.

The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents which may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like can be used.

The term "administering" as used herein is meant to provide any desired composition of the invention to a subject in any suitable manner.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the individual, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. For the desired effect, the daily dose of the extruded chewing gum of the present invention may be administered in an amount of 1 mg / kg to 10000 mg / kg, and may be administered once a day or divided into several times.

The pharmaceutical composition of the present invention may be administered to a subject in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.

The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the improvement of blood circulation or prevention or treatment of thrombotic diseases.

The composition of the present invention may be added to health functional foods for the purpose of improving blood circulation or preventing or improving thrombotic diseases. When the extruded chewing gum extract of the present invention is used as a food additive, the extruded chewing gum can be used as it is, or can be used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, the extruded chewing gum of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material in the production of food or beverage. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

There is no particular limitation on the kind of the food. Examples of the foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharine and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, preferred embodiments and experimental examples are presented to facilitate understanding of the present invention. However, the following examples and experimental examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples, experimental examples and production examples.

EXAMPLES Example 1: Manufacture of extrusion-molded chewing gum

Using a twin screw extruder for the production of the gum powder, a circular mold outlet having a diameter of 2 mm was opened and extruded at a temperature of 120 to 180 ° C and a pressure of 20 to 100 bar. Conditions for extrusion molding are shown in Table 1 below.

Example 2. Preparation of Extruded Chimpanzee Extract

10 g of the powder of the extruded chymotrypsin prepared in Example 1 was repeatedly extracted twice with low-temperature ethanol through a reflux extracting apparatus to obtain 2 g (20% yield) of a sample.

EXPERIMENTAL EXAMPLES 1. Analysis of Surface Content of Extruded Chimmae Extracts

The content of the indicator component of the extruded Chimpanzee extract prepared in Example 2 was confirmed by HPLC (High-performance liquid chromatography). The column temperature was set at 30 ° C using a Waters SunFire ^™ C18 (Waters Corp., Milford, USA), and the mobile phase was measured at 280 nm using a detector of H ₃ PO ₄ and acetonitrile. Table 2 shows the results.

Surface component Content (mg / g) Gum extract Extracted Chimma extract Gastrodin 6.34 3.68 p -hydroxybenzyl alcohol (HBA) 6.36 18.62 Vanillyl alcohol < RTI ID = 0.0 > 6.52 6.98 p -Hydroxybenzylaldehyde (HBAD) 1.54 1.32 Vanillin ND 0.26

As shown in Table 2, the results of analyzing the content before and after extrusion of five indicator elements are each Gasthof Rodin (Gastrodin) 6.34 mg / g and 3.68 mg / g, p - hydroxybenzyl alcohol (HBA; p -hydroxybenzyl alcohol) 6.36 mg / g and 18.62 mg / g, vanillyl alcohol (vanillyl alcohol) mg 6.52 / g and 6.98 mg / g, p- hydroxybenzyl aldehyde (HBAD; p- Hydroxybenzaldehyde) was 1.54 mg / g and 1.32 mg / g Vanillin was found to be 0.26 mg / g after extrusion. The results showed that the contents of p - hydroxybenzyl alcohol, vanillyl alcohol, p - hydroxybenzylaldehyde and vanillin were higher in the extract of extruded Ganoderma lucidum than that of the common Ganoderma lucidum extract.

Experimental Example 2: Experimental experiment using extruded Chimma extract

2-1. Toxicity test of Extruded Chimpanzee Extract

Lactate dehydratase (LDH) release experiments were performed to confirm the relationship between the effect of extruded chymase inhibiting platelet activation and cytotoxicity. The platelets were plated at 5 mg / ml and then incubated at 37 ° C. 100 μl platelets were then centrifuged at 12,000 × g for 1 minute. The supernatant (25 μl) was added to 100 μl of the NADH solution, and the absorbance was measured at a wavelength of 340 nm to confirm the release of LDH. The results are shown in Table 3.

Control DMSO
(0.5%) GE
(2 mg / ml) EXGE
(2 mg / ml) Digitonin
(50 M) LDH release (%) 7.61 ± 0.18 8.12 ± 0.08 7.43 ± 0.25 7.74 + 0.04 81.02 0.06

As shown in Table 3, it was confirmed that there was no significant change in the case of 2 mg / ml of chick (GE) and extruded chymase (EXGE) as compared with the normal control. This suggests that the inhibition of platelet activation of chimaeris and extruded rhizomes is not related to cytotoxicity on platelets.

2-2. Inhibitory Effect of Extracted Chimpanzee Extract on Platelet Aggregation

Platelet aggregation experiments were performed to confirm the inhibitory effect of extruded Chimmae extract on platelet aggregation. First, Sprague-Dawley (SD) rats were anesthetized with diethyl ether to obtain platelets. Blood was collected from the abdominal artery using sodium citrate (3.8%, 1: 9 v / v). The collected blood was centrifuged at 140 xg for 10 minutes to obtain platelet rich plasma (PRP), followed by centrifugation at 800 x g to obtain platelet-poor plasma (PPP) . PRP was fixed at 4 x 10 ⁸ platelets / ml. The platelets were treated with 0.5, 1, and 2 mg / ml of chondroitin and extruded platelets, respectively, and incubated at 37 ° C for 10 minutes. Then, platelet aggregation was induced with collagen or ADP, -2, USA). The results are shown in FIG.

As shown in FIG. 1, when platelet aggregation was induced by collagen or ADP, the inhibition of platelet aggregation was statistically significantly inhibited in the case of chromosomal and extruded chymase compared to the control, .

2-3. APTT and PT

Plasma coagulation time was measured by a coagulometer (Coatron M4, Germany) through endogenous pathway aPTT and extrinsic pathway PT to determine the effect of extruded Ganoderma lucidum extract on blood coagulation factors. First, human platelets were treated with 0.5, 1, and 2 mg / ml of extruded chymotrypsin, respectively, followed by incubation at 37 DEG C for 1 minute. aPTT was measured by adding 100 μl of aPTT measuring reagent and 100 μl of 20 mM CaCl _{2 to} 100 μl of a sample and measuring the exogenous pathway after adding 200 μl of a PT measuring reagent to 100 μl of a sample and the results are shown in Table 4 Respectively.

sample density aPTT (sec) PT (sec) Control group 48.87 + - 0.55 16.43 + - 0.35 Extracted Chimma extract

0.5 mg / ml 49.37 ± 0.64 15.17 ± 0.29  1 mg / ml 50.27 ± 0.06 15.37 ± 0.06  2 mg / ml 52.83 + - 0.71 17.50 + - 0.10 Heparin 0.5 IU 133.60 ± 3.12 19.30 ± 0.35

As shown in Table 4, it was confirmed that the coagulation time did not change with the extrusion-molded horse chestnut.

2-4. Thromboxane B of Extruded Chimpanzee Extract B ₂ Generation inhibitory effect

Extrusion thousand miles to extract this to determine the effect of the thromboxane B ₂ generation thromboxane B ₂ enzyme immunoassay ((EIA;. Enzyme immunoassay) the amount by using the kit were measured 0.5 to extrusion thousand miles extract in rat PRP , 1 and 2 mg / ml, followed by incubation for 10 minutes at 37 ° C. PRP was then treated with EDTA (2 mM) and indomethacin (50 uM) to stop production of thromboxane B ₂ × g. After centrifugation, the supernatant was measured with a thromboxane B ₂ enzyme immunoassay kit to confirm the amount of thromboxane B ₂ produced. The results are shown in FIG.

As shown in FIG. 2, both the chimma extract and the extruded chimma extract inhibited the production of thromboxane B ₂ statistically, compared with the control, and the inhibition of thromboxane B ₂ production .

Experimental Example 3: Animal Experiment Using Extruded Chimpanzee Extract

3-1. Inhibitory Effect of Extracted Chimpanzee Extract on Platelet Aggregation

Platelet aggregation was induced in order to confirm the inhibitory effect of extruded Chimmae extract on platelet aggregation. First, the rats were orally administered to the rats at a dose of 20, 100, or 500 mg / kg / day, and fasted on the day of the experiment. After PRP isolated from the blood of rats was incubated, platelet aggregation was induced with collagen and measured with an aggregometer (Chrono-Log 700-2, USA). The results are shown in FIG.

As shown in FIG. 3, the platelet aggregation inhibition was statistically significantly inhibited in both the chimma and the extruded chimneys compared to the control group, and it was confirmed that the platelet aggregation inhibition effect of the extruded chimma extract was better than that of the chimma extract.

3-2. APTT and PT

To determine the effect of extruded Ganoderma lucidum extract on blood coagulation factors, 20, 100 or 500 mg / kg / day extruded Ganoderma lucidum extract was orally administered to rats for one week. After incubation, 100 μl of aPTT assay reagent and 100 μl of 20 mM CaCl ₂ were added to 100 μl of PPP, and 200 μl of PT assay reagent was added to 100 μl of PPP And the results are shown in Table 5. < tb >< TABLE >

Group Dose (mg / kg) aPTT (sec) PT (sec) Normal 17.11 + 0.83 25.15 占 1.21 Extracted Chimma extract 20 15.90 + - 0.76 26.93 ± 1.20 100 17.49 + 0.26 26.27 + - 2.38 500 17.84 ± 0.51 26.29 + 0.44 aspirin 20 16.60 ± 0.36 24.14 + 0.11

As shown in Table 5, it was confirmed that the extruded Chimma extract in aPTT and PT did not change plasma coagulation time.

3-3. Bleeding time in extrusion-processed Ganoderma lucidum extract treatment

To determine whether platelets and plasma factors were abnormal, we measured the effect of extruded Chimmae extract on bleeding time. Bleeding time was measured by the Hornstra method. After anesthetizing with ketamine and rum poured into the abdominal cavity, 3 mm of the tail of the rat was cut and the time was measured until the hemostasis was achieved by soaking in 0.9% physiological saline maintained at 37 ° C. The results are shown in Table 6.

Group Dose (mg / kg) Bleeding time (sec) Normal 647.67 ± 63.69 Extracted Chimma extract

20 698.00 ± 28.79 100 917.67 ± 107.198 ^* 500 1027.33 + - 66.73 ^** aspirin 20 1200.00 ± 0.00 ^**

As shown in Table 6, it was confirmed that the bleeding time was significantly longer in the treatment of extruded Chimmae extract than in the control group.

Hereinafter, formulation examples of the pharmaceutical composition and the food composition of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.

Formulation Example 1. Pharmaceutical preparation

1-1. Manufacture of Powder

Extruded Chicken 20 mg

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

1-2. Manufacture of tablets

Extruded Chunma 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

1-3. Preparation of capsules

Extruded Chunma 10 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

1-4. Injection preparation

Extruded Chunma 10 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ .2H ₂ O 26 mg

(2 ml) per 1 ampoule in accordance with the usual injection preparation method.

1-5. Manufacture of liquid agent

Extruded Chicken 20 mg

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.

Formulation Example 2. Food preparation

2-1. Manufacture of health food

Extrusion castor oil 100 mg

Vitamin mixture quantity

Vitamin A acetate 70 μg

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

Vitamin B12 0.2 μg

Vitamin C 10 mg

Biotin 10 μg

Nicotinic acid amide 1.7 mg

Folic acid 50 μg

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

2-2. Manufacture of health drinks

Extrusion castor oil 100 mg

Vitamin C 15 g

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B1 0.25 g

Vitamin B2 0.3 g

Water quantity

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 liter container, It is used in the production of the health beverage composition of the invention.

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Claims (9)

A pharmaceutical composition for improving circulation containing an extract of Gastrodia elata Blume as an active ingredient The pharmaceutical composition for improving blood circulation according to claim 1, wherein the extrusion molding is performed at a temperature of 120 to 180 ° C and a pressure of 20 to 100 bar. [Claim 2] The pharmaceutical composition for improving circulation according to claim 1, wherein the extruded chewing gum extract is extracted with a solvent selected from water, an alcohol having 1 to 4 carbon atoms, or a mixed solution thereof. The pharmaceutical composition for improving circulation according to claim 3, wherein the alcohol is methanol or ethanol. The pharmaceutical composition for improving circulation according to claim 1, wherein the composition inhibits platelet aggregation. A composition for improving circulation comprising an extract of Gastrodia elata Blume as an active ingredient. A pharmaceutical composition for preventing or treating a thrombotic disease comprising an extruded chimme extract as an active ingredient. The method according to claim 7, wherein the thrombotic disease is selected from the group consisting of arterial thrombosis, venous thrombosis, pulmonary embolism, chronic venous ischemia, varicose veins, deep vein thrombosis, arteriosclerosis, cerebral hemorrhage, stroke and cerebral infarction. A pharmaceutical composition for preventing or treating diseases. A food composition for prevention or improvement of a thrombotic disease comprising an extruded chimme extract as an active ingredient.

Images